Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan

Journal of Medical Economics

Volumn 18, Issue 7, 2015, Pages 502-511

  Kuwabara, Hiroyo ^a   Westerhout, Kirsten ^b   Treur, Maarten ^b   Cerri, Karin ^c,d   Mahlich, Joerg ^a,e   Yatsuhashi, Hiroshi ^f  

^a Janssen Pharmaceutical KK   (Japan)

^b PHARMERIT INTERNATIONAL   (Netherlands)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

Cost effectiveness; Hepatitis C; Simeprevir; Telaprevir

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; ANTIVIRUS AGENT; INTERFERON;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HOSPITAL COST; HUMAN; JAPAN; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; HEPATITIS C, CHRONIC; MARKOV CHAIN; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PHENOTYPE; STATISTICAL MODEL;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; JAPAN; MALE; MARKOV CHAINS; META-ANALYSIS AS TOPIC; MIDDLE AGED; MODELS, ECONOMETRIC; PHENOTYPE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; SIMEPREVIR;

EID: 84941628082     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1029492     Document Type: Article

References (33)

1. Ministry of Health, Labour and Welfare. National Health Expenditure 2012. Tokyo, 2014. http://www.mhlw.go.jp/toukei/list/37-21.html. Accessed October 17, 2014
2. Bennett WG, Inoue Y, Beck R, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mile chronic hepatitis C. Ann Intern Med 1997;127:855-65
3. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alpha and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4:1-67
4. Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:1-125
5. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37
6. Ishida H, Inoue Y, Wong JB, et al. Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial. Hepatol Res 2004;28:125-36
7. Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-8
8. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010;53:39-43
9. Kuboki M, Iino S, Okuno T, et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. Hepatology 2007;22:645-52
10. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-na?ve patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012;56:78-84
11. Hayashi, N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-na?ve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014;61:219-27
12. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int 2012;32:32-8
13. Wright M, Grieve R, Roberts J, et al. UK mild hepatitis C trial investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomized controlled trial and economic evaluation. Health Technol Assess 2006; 10:1-113
14. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010;52: 518-27
15. Okanoue T, Minami M, Makiyama A, et al. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastoroenterol Hepatol 2005;10(2 Suppl):S89-91
16. Ministry of Health, Labour and Welfare. Life table. Tokyo, 2013. http://www.mhlw.go.jp/toukei/saikin/hw/life/life12/index.html. Accessed June 26, 2014
17. Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-210
18. Ministry of Health, Labour and Welfare. Guideline for economic evaluation of healthcare technologies in Japan. Tokyo, 2013. http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000033418.pdf. Accessed August 25, 2014
19. Toshikuni N, Izumi A, Nishino K, et al. Comparison of outcomes between patients with alcoholic cirrohosis and those with hepatitis C virus-related cirrhosis. J Gastoroenterol and Hepatol 2009;24:1276-83
20. Imazeki F, Yokosuka O, Fukai K, et al. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int 2005;25:772-8
21. Japanese liver transplantation society. Liver transplantation in Japan-registry by the Japanese liver transplantation society. Ishoku 2012;47:416-28
22. Quigley JM, Bryden PA, Scott DA, et al. The relative efficacy and safety of simeprevir and telaprevir in treatment-na?ve hepatitis C infected patients in a Japanese population-Bayesian network meta-analysis. Hepatol Res (in press). DOI: 10.1111/hepr.12467
23. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-na?ve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastoroenterol 2014;49:138-47
24. Yatsuhashi H. Research for the treatment of liver cirrhosis. Report of MHLW urgent measures against hepatitis by research grant of Ministry of Health, Labour and Welfare. Tokyo: MHWL, 2007
25. Ministry of Health, Labour and Welfare. Drug Price List. Tokyo, 2014. http://www.mhlw.go.jp/topics/2014/03/tp0305-01.html. Accessed October 9, 2014
26. Ministry of Health, Labour and Welfare. Medical Fee Table. Tokyo, 2014. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000032996.html. Accessed October 9, 2014
27. Ishida K, Imai H, Ogasawara K, et al. Cost-utility of living donor liver transplantation in a single Japanese center. Hepatogastroenterology 2006;53: 588-91
28. WHO. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Geneva, 2013. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Accessed September 3, 2014
29. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Eng J Med 2011; 364:2405-16
30. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alpha 2a plus ribavirin in treatment-na?ve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet 2014;384:403-13
31. Moriyama M, Matsumura H, Aoki H, et al. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver Int 2005;25:85-90
32. Nakamura J, Terajima K, Aoyagi Y, et al. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the highrisk groups. Tohoku J Exp Med 2008;215:33-42
33. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and metaregression. Hepatology 2008;48:419-31